ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
-1,03%
Bitcoin
63 121,06
6,77%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. SAB Biotherapeutics Inc (SABS)

  7. SAB Biotherapeutics Inc (SABS) Actualités

SABS SAB Biotherapeutics Inc

4,03
0,01 (0,25%)
Après les heures de négociation
Dernière mise à jour : 23:16:11
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
SAB Biotherapeutics Inc SABS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,01 0,25% 4,03 23:16:11
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,00 4,00 4,1002 4,03 4,02
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
16/4/202413:15GLOBESAB Biotherapeutics Provides SAB-142 Trial Update
08/4/202413:15GLOBESAB Biotherapeutics to Present at INNODIA Annual Meeting
04/4/202413:15GLOBESAB Biotherapeutics to Present at the Needham Virtual..
29/3/202412:15GLOBESAB Biotherapeutics Reports Full Year 2023 Operating and..
25/3/202415:15GLOBESAB Biotherapeutics Announces Clinical Partnership with..
08/3/202422:30EDGAR2Form 8-K - Current report
23/2/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202414:00GLOBESAB Biotherapeutics to Present at the BIO CEO & Investor..
08/2/202414:00GLOBESAB Biotherapeutics to Present at the Oppenheimer..
02/2/202413:53EDGAR2Form 8-K - Current report
02/2/202413:30GLOBESAB Biotherapeutics Announces Executive Leadership Change
26/1/202422:15EDGAR2Form 8-K - Current report
26/1/202422:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
25/1/202423:00EDGAR2Form 8-K - Current report
23/1/202423:58GLOBESAB Biotherapeutics Regains Compliance with Nasdaq Minimum..
19/1/202422:21EDGAR2Form 8-K - Current report
03/1/202415:00EDGAR2Form 8-K - Current report
02/1/202422:30GLOBESAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
18/12/202315:34EDGAR2Form DEF 14A - Other definitive proxy statements
08/12/202323:26EDGAR2Form PRE 14A - Other preliminary proxy statements
30/11/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202313:40EDGAR2Form 8-K - Current report
29/11/202313:30GLOBESAB Biotherapeutics Announces Commencement of the HUMAN..
29/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
28/11/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202322:45EDGAR2Form 8-K - Current report
20/11/202323:00EDGAR2Form 8-K - Current report
20/11/202322:45EDGAR2Form S-3/A - Registration statement under Securities Act of..
20/11/202313:30GLOBESAB Biotherapeutics Appoints Katie Ellias to the Board of..
15/11/202301:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202313:30GLOBESAB Biotherapeutics Announces Completion of $67.1 Million..
14/11/202313:15GLOBESAB Biotherapeutics Announces Q3 2023 Financial Results and..
13/11/202322:48EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:30GLOBESAB Biotherapeutics to Present at Piper Sandler Healthcare..
03/11/202322:00EDGAR2Form S-3 - Registration statement under Securities Act of..
03/11/202321:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/10/202322:00EDGAR2Form DEF 14A - Other definitive proxy statements
27/10/202323:00EDGAR2Form 8-K - Current report
24/10/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202313:30GLOBESAB Biotherapeutics Appoints Michael G. King Jr. as Chief..
20/10/202322:30EDGAR2Form PRE 14A - Other preliminary proxy statements
19/10/202313:30GLOBESAB Biotherapeutics Receives Australian Approval to Commence..
05/10/202313:30GLOBESAB Biotherapeutics Approves Appointment of Andrew Moin to..
02/10/202322:10EDGAR2Form 8-K - Current report
02/10/202313:30GLOBESAB Biotherapeutics Announces Private Placement of up to..
21/8/202322:15EDGAR2Form S-3 - Registration statement under Securities Act of..
21/8/202314:30GLOBESAB Biotherapeutics Provides Company Update for Q2..
21/8/202314:25EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
SABS
SAB Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés